<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353339</url>
  </required_header>
  <id_info>
    <org_study_id>CIHR MOP 222493, 2010-292</org_study_id>
    <nct_id>NCT01353339</nct_id>
  </id_info>
  <brief_title>Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study</brief_title>
  <official_title>Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Paul's Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vancouver General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Joseph's Healthcare Hamilton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Research Questions:&#xD;
&#xD;
      Efficacy, safety and feasibility of a 3-month course of levofloxacin in a pilot study will be&#xD;
      assessed.&#xD;
&#xD;
        1. Under efficacy, this pilot will determine whether levofloxacin can decrease the&#xD;
           incidence of BK viruria and peak urine BK viral load.&#xD;
&#xD;
        2. Under safety, this pilot will determine the incidence of adverse events with&#xD;
           levofloxacin.&#xD;
&#xD;
        3. Under feasibility, this pilot will determine the number of kidney transplant patients&#xD;
           randomized over an eight month enrolment period, adherence to the levofloxacin and&#xD;
           frequency of patient drop-out and loss to follow-up&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BK virus infection has emerged as a major complication in renal transplantation leading to a&#xD;
      significant reduction in graft survival. There are currently no proven strategies to prevent&#xD;
      or treat BK virus infection. Quinolone antibiotics, such as levofloxacin, have demonstrated&#xD;
      activity against BK virus. The investigators hypothesize that administration of a quinolone&#xD;
      antibiotic, when given early post-transplantation, will prevent the establishment of BK viral&#xD;
      replication in the urine and thus prevent systemic BK virus infection. A non-randomized study&#xD;
      in kidney transplant recipients found that patients given levofloxacin or ciprofloxacin had a&#xD;
      significantly lower incidence of BK viremia compared to those not receiving a quinolone (4%&#xD;
      versus 24.5%, P=0.02).&#xD;
&#xD;
      Objective: The primary objective of the full trial will be to determine if the quinolone&#xD;
      levofloxacin decreases the occurrence of doubling creatinine, transplant failure or death in&#xD;
      kidney transplant recipients. The aim of this pilot trial is to assess the efficacy, safety&#xD;
      and feasibility of a 3-month course of levofloxacin in the kidney transplant population.&#xD;
&#xD;
      Results from this pilot study will provide vital information to design and conduct a large,&#xD;
      multi-centre trial to determine if quinolone therapy decreases meaningful clinical outcomes&#xD;
      in kidney transplantation. If levofloxacin significantly reduces BK viruria and urine viral&#xD;
      loads in kidney transplantation it will provide important justification of biologic effect to&#xD;
      progress to the larger trial. If the full trial shows that levofloxacin significantly reduces&#xD;
      BK infection and improves outcomes, its use in renal transplantation will be strongly&#xD;
      endorsed given the lack of proven therapies for this condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: The time to occurence of BK viruria</measure>
    <time_frame>12 months post-transplantation</time_frame>
    <description>BK viruria will be defined as ≥1000 copies/mL ok BK virus DNA in the urine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence and type of all adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute rejection</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of Acute rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridium difficile associated diarrhea</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of microbiologically confirmed clostridium difficile associated diarrhea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of other infections (viral, bacterial and fungal) based on established guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quinolone resistance</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of quinolone resistance where a quinolone would have been a therapeutic option</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of levofloxacin on immunosuppressive drug doses and blood levels</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients transplanted</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients transplanted during the 8 month recruitment period who are randomized into the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of randomized participants who are adherent to the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of quinolones</measure>
    <time_frame>12 months</time_frame>
    <description>Use of quinolones outside of the protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patient drop-out and loss to follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative BK urine viral load</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BK viremia</measure>
    <time_frame>12 months</time_frame>
    <description>Time to occurence of BK viremia, defined as ≥250 copies/mL of BK virus DNA in the plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Disease Due to BK Polyomavirus</condition>
  <condition>Kidney Transplant Infection</condition>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>levofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>500mg, PO, once daily for 3 months</description>
    <arm_group_label>levofloxacin</arm_group_label>
    <arm_group_label>sugar pill</arm_group_label>
    <other_name>Apo-levofloxacin</other_name>
    <other_name>DIN 02284707</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  a primary or repeat kidney transplant recipient (deceased or living donor)&#xD;
&#xD;
          -  age greater or equal to 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
&#xD;
          -  Greater than 5 days post-transplantation&#xD;
&#xD;
          -  BK virus nephropathy with a previous transplant&#xD;
&#xD;
          -  History of allergic reaction to any quinolone antibiotic&#xD;
&#xD;
          -  History of quinolone associated tendonitis or tendon rupture&#xD;
&#xD;
          -  Corrected QT interval prolongation on EKG as defined by Al-Khatib&#xD;
&#xD;
          -  Concomitant use of medication known to prolong the QT interval such as class IA&#xD;
             antiarrhythmic drugs (e.g. quinidine, procainamide, disopyramide), class III&#xD;
             antiarrhythmic drugs (e.g. amiodarone, sotalol), azole antifungals (e.g. fluconazole)&#xD;
             or macrolide antibiotics (e.g. erythromycin)&#xD;
&#xD;
          -  Pregnant or breastfeeding as safety of levofloxacin not established&#xD;
&#xD;
          -  Requires quinolone antibiotic for more than 14 days (e.g. for UTI prophylaxis)&#xD;
&#xD;
          -  Recipient of a multi-organ transplant (e.g. kidney-pancreas)&#xD;
&#xD;
          -  Currently enrolled in another interventional trial&#xD;
&#xD;
          -  Previously enrolled in this study&#xD;
&#xD;
          -  History of rhabdomyolysis&#xD;
&#xD;
          -  Significant allergic reaction to ≥ 3 classes of antibiotics as these patients may have&#xD;
             no other option other than quinolones for routine infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Knoll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Capital Health - University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winnipeg Health Science Center</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Science Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Science Center</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2011</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Transplant</keyword>
  <keyword>BK Polyomavirus Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

